IMMUNOVANT INC (IMVT) Stock Price, Quote, News and Overview
NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD
IMVT Quote, Performance and Key Statistics
15.9
-0.25 (-1.55%)
The current stock price of IMVT is 15.9 USD. In the past month the price decreased by -3.17%. In the past year, price decreased by -44.91%.
IMVT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.83 | 342.01B | ||
| AMGN | AMGEN INC | 14.32 | 152.57B | ||
| GILD | GILEAD SCIENCES INC | 13.34 | 128.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1720.21 | 128.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.32 | 64.50B | ||
| ARGX | ARGENX SE - ADR | 336.79 | 39.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.19B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.55B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.62B | ||
| NTRA | NATERA INC | N/A | 20.46B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.19B | ||
| BIIB | BIOGEN INC | 7.34 | 17.70B |
Related stock screener links
About IMVT
Company Profile
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 207 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Company Info
IMMUNOVANT INC
320 West 37Th Street
New York City NEW YORK 10018 US
CEO: Peter Salzmann
Employees: 207
Company Website: https://immunovant.com/
Investor Relations: https://www.immunovant.com/investors
Phone: 19175803099
IMMUNOVANT INC / IMVT FAQ
What is the stock price of IMMUNOVANT INC today?
The current stock price of IMVT is 15.9 USD. The price decreased by -1.55% in the last trading session.
What is the ticker symbol for IMMUNOVANT INC stock?
The exchange symbol of IMMUNOVANT INC is IMVT and it is listed on the Nasdaq exchange.
On which exchange is IMVT stock listed?
IMVT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNOVANT INC stock?
21 analysts have analysed IMVT and the average price target is 46.14 USD. This implies a price increase of 190.16% is expected in the next year compared to the current price of 15.9. Check the IMMUNOVANT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNOVANT INC worth?
IMMUNOVANT INC (IMVT) has a market capitalization of 2.70B USD. This makes IMVT a Mid Cap stock.
How many employees does IMMUNOVANT INC have?
IMMUNOVANT INC (IMVT) currently has 207 employees.
What are the support and resistance levels for IMMUNOVANT INC (IMVT) stock?
IMMUNOVANT INC (IMVT) has a support level at 15.08 and a resistance level at 15.91. Check the full technical report for a detailed analysis of IMVT support and resistance levels.
Should I buy IMMUNOVANT INC (IMVT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMVT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMVT, evaluating the profitability, health, valuation and growth aspects
- IMMUNOVANT INC (IMVT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNOVANT INC (IMVT) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNOVANT INC (IMVT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNOVANT INC (IMVT) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNOVANT INC (IMVT) Stock Chart to make your own analysis
- IMMUNOVANT INC (IMVT) Latest news and press-releases to stay up to date.
Does IMMUNOVANT INC (IMVT) stock pay dividends?
IMVT does not pay a dividend.
When does IMMUNOVANT INC (IMVT) report earnings?
IMMUNOVANT INC (IMVT) will report earnings on 2025-05-30, after the market close.
What is the Price/Earnings (PE) ratio of IMMUNOVANT INC (IMVT)?
IMMUNOVANT INC (IMVT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.62).
What is the Short Interest ratio of IMMUNOVANT INC (IMVT) stock?
The outstanding short interest for IMMUNOVANT INC (IMVT) is 30.72% of its float. Check the ownership tab for more information on the IMVT short interest.
IMVT Technical Analysis
IMVT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMVT. IMVT has a great financial health rating, but its profitability evaluates not so good.
IMVT Financial Highlights
Over the last trailing twelve months IMVT reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -42.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.92% | ||
| ROE | -108.53% | ||
| Debt/Equity | 0 |
IMVT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to IMVT. The Buy consensus is the average rating of analysts ratings from 21 analysts.